MCK vs STEK
Mckesson Corp. and Stemtech Corp., side by side — 6 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | MCK | STEK |
|---|---|---|
| Revenue | $403.4B | $2.9M |
| Net income | $4.8B | $-4.0M |
| Gross margin | 3.6% | 80.3% |
| Net margin | 1.3% | −140.8% |
| Return on equity | — | — |
| Diluted EPS | $38.38 | −$0.02 |
| Dividend / share | $3.17 | — |
| Payout ratio | 8.0% | — |
| Free cash flow | $5.7B | $-483,583 |
| Equity | $-2.2B | $-7.0M |
| Net debt / equity | — | — |
| Current ratio | 0.85× | 0.04× |
| Revenue CAGR 5y | 11.1% | −8.1% |
| Profit CAGR 5y | — | — |
MCK bills 140256.2× the revenue of STEK, and STEK closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Revenue by year
6 years side by side
| Fiscal year | MCK | STEK |
|---|---|---|
| FY2025 | $403.4B | $2.9M |
| FY2024 | $359.1B | $5.1M |
| FY2023 | $309.0B | $4.9M |
| FY2022 | $276.7B | $4.6M |
| FY2021 | $264.0B | $4.3M |
| FY2020 | $238.2B | $4.4M |
Net income by year
Bottom line
| Fiscal year | MCK | STEK |
|---|---|---|
| FY2025 | $4.8B | $-4.0M |
| FY2024 | $3.3B | $-3.8M |
| FY2023 | $3.0B | $-5.4M |
| FY2022 | $3.6B | $-8.5M |
| FY2021 | $1.1B | $-7.1M |
| FY2020 | $-4.5B | $-916,697 |